Please login to the form below

Not currently logged in
Email:
Password:

X4 appoints John Celebi as COO

He joins from Igenica Biotherapeutics

X4 Pharmaceuticals John CelebiCambridge, Massachusetts-based X4 Pharmaceuticals has appointed John Celebi as its new chief operating officer.

Celebi brings over 20 years of biotech industry experience to the role, and will take on responsibility for X4's business development, operations and corporate development.

Most recently, he served as chief business officer of Igenica Biotherapeutics, and has previously held senior positions at Agilent Technologies, ArQule, Biogen and Cyclis Pharmaceuticals.

Paula Regan, president and chief executive of X4, said: “John has a tremendous knowledge-base for evolving an emerging biotech company across the range of critical business capabilities.

“His experience will be essential to achieving X4's mission of developing novel CXCR4 therapies that have the potential to make a significant impact in the cancer treatment landscape, and we look forward to tapping into his business-building expertise as we continue to pursue the development of X4P-001 and our portfolio of CXCR4 inhibitors.”

22nd June 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics